3Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP)Expert Panel on Detection, Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [ J] . JAMA, 2001,285 ( 19 ) : 2 486 - 2 497.
4De Schoenmakere G, Chauveau D, Grunfeld JP. Enzyme replacement therapy in Anderson -Fabry's disease:beneficial clinical effect on vital organ function [ J]. NephrolDial Transplant,2003, 18(1) :33 -35.
5Amanda IA, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes : prospective observational study [ J ]. Br Med J,2000,321 (7258) :412 -419.
6Vinik AL, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes[J]. Diabetes Care,2001,24(8) :1 476 -1 485.
8Zhang XF, Attia J, DpEste C, et al. Prevalence and magnitude of classical risk factors for stroke in a cohort of 5 092 Chinese steel-workers over 13.5 years offollow - up [ J ]. Stroke, 2004,35 ( 5 ) : 1 052-1 056.
9Wolf PA, DpAgostino RB, Kannel WB, et al. Cigarette smoking as a risk factor forstroke: the Framingham study [J]. JAMA, 1988,259(7) :1 025 -1 029.
10Lavados PM, Hennis A J, Femandes JG,et al. Stroke epidemiology, prevention, andmanagernent strategies at a regional level: Latin America and the Caribbean [ J]. LancetNeurol, 2007,6 (4) :362 -372.
10Grigoryan M,Geisler S D,St Louis E K,et al.Cerebral arteriolarthromboembolism in idiopathic hypereosinophilic syndrome[J].Arch Neu-rol,2009,66(4):528-531.
